Posted by Michael Wonder on 03 Feb 2022
Timely intervention: first chronic kidney disease treatment in 20 years
3 February 2022 - Significant landmark as NICE recommends AstraZeneca's chronic kidney disease treatment Forxiga
NICE has issued a Final Appraisal Document recommending AstraZeneca’s Forxiga (dapagliflozin) within its marketing authorisation for the treatment of adults with chronic kidney disease.
